Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS

Lung cancer remains the most lethal malignancy in the world. Despite improvements in surgical treatment, systemic therapy, and radiotherapy, the 5-year survival rate for all patients diagnosed with lung cancer remains between 15 and 20%. Newer therapeutic strategies rely on specific molecular altera...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Korpanty, Grzegorz J., Graham, Donna M., Vincent, Mark D., Leighl, Natasha B.
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2014
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4127527/
https://ncbi.nlm.nih.gov/pubmed/25157335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2014.00204
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars